Summary
Photoredox catalysis (the use of visible-light to accelerate chemical reactions) has emerged as a uniquely valuable platform in organic chemistry, facilitating the use of native functionality to construct new C–C bonds. The key aim of this research is the unification of photoredox catalysis and bioconjugation to specifically target 3-nitrotyrosine (3NT) – a critical biomarker for the diagnosis of several diseases including Alzheimer's, heart disease, and stroke, in order to facilitate the rapid identification and mapping of this important residue within the proteome. Current chemical strategies to functionalize 3NT residues are hampered by harsh chemical conditions and poor site-selectivity; therefore, the development of a novel platform based upon the use of visible-light will have far-reaching implications in terms of identifying early-stages of disease and the development of new therapeutic strategies.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/891458 |
| Start date: | 01-04-2020 |
| End date: | 31-03-2022 |
| Total budget - Public funding: | 189 099,84 Euro - 189 099,00 Euro |
Cordis data
Original description
Photoredox catalysis (the use of visible-light to accelerate chemical reactions) has emerged as a uniquely valuable platform in organic chemistry, facilitating the use of native functionality to construct new C–C bonds. The key aim of this research is the unification of photoredox catalysis and bioconjugation to specifically target 3-nitrotyrosine (3NT) – a critical biomarker for the diagnosis of several diseases including Alzheimer's, heart disease, and stroke, in order to facilitate the rapid identification and mapping of this important residue within the proteome. Current chemical strategies to functionalize 3NT residues are hampered by harsh chemical conditions and poor site-selectivity; therefore, the development of a novel platform based upon the use of visible-light will have far-reaching implications in terms of identifying early-stages of disease and the development of new therapeutic strategies.Status
CLOSEDCall topic
MSCA-IF-2019Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
